FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer

Coverage, in order

1. 9d ago
   FDA Drug Safety / Drugs feed indie

   FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer

   On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon c

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.